2P8-11682-83679
3 vaccinations
1 coded response
20 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 618 / IL
- Registered
- 2021-02-17
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-17
Registered in v-safe
-
2021-02-17
Dose 1 — Pfizer-BioNTech
- 2021-02-17
-
2021-02-18
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Site: Pain · Fever · Fatigue or tiredness · Be unable to work, Be unable to do your normal daily activitiesAdult check-in
-
2021-02-19
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-02-20
- 2021-02-21
- 2021-02-22
- 2021-02-23
- 2021-02-24
- 2021-03-03
-
2021-03-10
Dose 2 — Pfizer-BioNTech
- 2021-03-26
- 2021-04-02
- 2021-04-07
- 2021-04-14
- 2021-04-21
- 2021-06-09
- 2021-09-08
-
2022-03-10
Survey response — 12 months, dose 2MedDRA: Ageusia, Arthralgia, Cough, Pain, Rhinorrhoea — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Body pain, joint pain, cough, runny nose, loss of tasteMedDRA releases: 2024-11 · check-in free text available
-
2022-03-10
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2022-03-11
-
2022-10-07
Dose 3 — Moderna
-
2022-10-12
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
-
2022-10-14
Health check-in — day 7, dose 3Feeling: Fair · Fatigue or tiredness · Be unable to work or attend schoolAdult check-in
- 2023-04-07
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-17 | Pfizer-BioNTech | |
| 2 | 2021-03-10 | Pfizer-BioNTech | |
| 3 | 2022-10-07 | Moderna | No |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-03-10 | Unsuccessful |
Free text
Release 11 — 12 months, dose 2
Symptoms: Body pain, joint pain, cough, runny nose, loss of taste
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Arthralgia | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release